# Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia

> **NCT03333005** · PHASE1 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** APX001 with Standard of Care anti-fungal agent

## Key facts

- **NCT ID:** NCT03333005
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333005, "Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03333005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*